Ablation of phosphoinositide-3-kinase class II alpha suppresses hepatoma cell proliferation

Biochemical and Biophysical Research Communications

Volumn 387, Issue 2, 2009, Pages 310-315

  Ng, Stanley K L ^a   Neo, Soek Ying ^a   Yap, Yann Wan ^a   Karuturi, R Krishna Murthy ^b   Loh, Evelyn S L ^b   Liau, Kui Hin ^c   Ren, Ee Chee ^a,d  

^a AGENCY FOR SCIENCE   (Singapore)

^b GENOME INSTITUTE OF SINGAPORE   (Singapore)

^c TAN TOCK SENG HOSPITAL   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Apoptosis; Cell growth; HCC; Liver; Phosphoinositide 3 kinase; PI3K; PIK3C2

Indexed keywords

CASPASE 3; ISOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE 2ALPHA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CATALYSIS; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMING UNIT; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE DOSAGE; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BASE SEQUENCE; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CELL PROLIFERATION; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED;

EID: 67949091004     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.07.013     Document Type: Article

References (34)

1. van't Veer L.J., and Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 452 (2008) 564-570
2. Llovet J.M., Burroughs A., and Bruix J. Hepatocellular carcinoma. Lancet 362 (2003) 1907-1917
3. Parkin D.M., Bray F., Ferlay J., and Pisani P. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94 (2001) 153-156
4. Pang R.W., and Poon R.T. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72 Suppl. 1 (2007) 30-44
5. Vivanco I., and Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
6. Vanhaesebroeck B., and Waterfield M.D. Signaling by distinct classes of phosphoinositide 3-kinases. Exp. Cell Res. 253 (1999) 239-254
7. Hawkins P.T., Anderson K.E., Davidson K., and Stephens L.R. Signalling through class I PI3Ks in mammalian cells. Biochem. Soc. Trans. 34 (2006) 647-662
8. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
9. Bader A.G., Kang S., and Vogt P.K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. USA 103 (2006) 1475-1479
10. Lee J.W., Soung Y.H., Kim S.Y., Lee H.W., Park W.S., Nam S.W., Kim S.H., Lee J.Y., Yoo N.J., and Lee S.H. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 24 (2005) 1477-1480
11. Tanaka Y., Kanai F., Tada M., Asaoka Y., Guleng B., Jazag A., Ohta M., Ikenoue T., Tateishi K., Obi S., Kawabe T., Yokosuka O., and Omata M. Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients. Oncogene 25 (2006) 2950-2952
12. Neo S.Y., Leow C.K., Vega V.B., Long P.M., Islam A.F., Lai P.B., Liu E.T., and Ren E.C. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology 39 (2004) 944-953
13. Dowsett M., and Dunbier A.K. Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clin. Cancer Res. 14 (2008) 8019-8026
14. Riese D.J., and Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20 (1998) 41-48
15. Grant S., Qiao L., and Dent P. Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 7 (2002) d376-d389
16. Tay N., Chan S.H., and Ren E.C. Detection of integrated hepatitis B virus DNA in hepatocellular carcinoma cell lines by nonradioactive in situ hybridization. J. Med. Virol. 30 (1990) 266-271
17. Bressac B., Galvin K.M., Liang T.J., Isselbacher K.J., Wands J.R., and Ozturk M. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc. Natl. Acad. Sci. USA 87 (1990) 1973-1977
18. Logue S.E., and Martin S.J. Caspase activation cascades in apoptosis. Biochem. Soc. Trans. 36 (2008) 1-9
19. Villanueva A., Chiang D.Y., Newell P., Peix J., Thung S., Alsinet C., Tovar V., Roayaie S., Minguez B., Sole M., Battiston C., Van L.S., et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135 (2008) 1972-1983
20. Rizell M., Andersson M., Cahlin C., Hafstrom L., Olausson M., and Lindner P. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int. J. Clin. Oncol. 13 (2008) 66-70
21. Lee Y.I., Kang-Park S., Do S.I., and Lee Y.I. The hepatitis B virus-X protein activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 276 (2001) 16969-16977
22. Street A., Macdonald A., Crowder K., and Harris M. The hepatitis C virus NS5A protein activates a phosphoinositide 3-kinase-dependent survival signaling cascade. J. Biol. Chem. 279 (2004) 12232-12241
23. Guerreiro A.S., Fattet S., Fischer B., Shalaby T., Jackson S.P., Schoenwaelder S.M., Grotzer M.A., Delattre O., and Arcaro A. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance and migration. Clin. Cancer Res. 14 (2008) 6761-6769
24. Leverrier Y., Okkenhaug K., Sawyer C., Bilancio A., Vanhaesebroeck B., and Ridley A.J. class I phosphoinositide 3-kinase p110beta is required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by macrophage. J. Biol. Chem. 278 (2003) 38437-38442
25. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., Zhang J., Signoretti S., Loda M., Roberts T.M., and Zhao J.J. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesiss. Nature 454 (2008) 776-779
26. Zhang T.T., Okkenhaug K., Nashed B.F., Puri K.D., Knight Z.A., Shokat K.M., Vanhaesebroeck N., and Marshall A.J. Genetic or pharmaceutical blockade of p110delta phosphoinositide 3-kinase enhances IgE production. J. Allergy Clin. Immunol. 122 (2008) 811-819
27. Maira S.-M., Stauffer F., Schnell C., and García-Echeverría C. PI3K inhibitors for cancer treatment: where do we stand?. Biochem. Soc. Trans. 37 (2009) 265-272
28. Falasca M., Hughes W.E., Dominguez V., Sala G., Fostira F., Fang M.Q., Cazzolli R., Shepherd P.R., James D.E., and Maffucci T. The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J. Biol. Chem. 282 (2007) 28226-28236
29. Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D., and Domin J. Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors. Mol. Cell. Biol. 20 (2000) 3817-3830
30. Ktori C., Shepherd P.R., and O'Rourke L. TNF-alpha and leptin activate the alpha-isoform of class II phosphoinositide 3-kinase. Biochem. Biophys. Res. Commun. 306 (2003) 139-143
31. 2+-induced, Rho- and Rho kinase-dependent regulation of myosin phosphatase and contraction in isolated vascular smooth muscle cells. Mol. Pharmacol. 71 (2007) 912-920
32. Meunier F.A., Osborne S.L., Hammond G.R., Cooke F.T., Parker P.J., Domin J., and Schiavo G. Phosphatidylinositol 3-kinase C2alpha is essential for ATP-dependent priming of neurosecretory granule exocytosis. Mol. Biol. Cell 16 (2005) 4841-4851
33. Kang S., Song J., Kang J., Kang H., Lee D., Lee Y., and Park D. Suppression of the alpha-isoform of class II phosphoinositide 3-kinase gene expression leads to apoptotic cell death. Biochem. Biophys. Res. Commun. 329 (2005) 6-10
34. Elis W., Triantafellow E., Wolters N.M., Sian K.R., Caponigro G., Borawski J., Gaither L.A., Murphy L.O., Finan P.M., and Mackeigan J.P. Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death. Mol. Cancer Res. 6 (2008) 614-623